Holen Sie sich die Stockscreener-App
21.72
3.87%
0.81
Schlusskurs vom Vortag:
$20.91
Offen:
$21
24-Stunden-Volumen:
1.78M
Relative Volume:
1.22
Marktkapitalisierung:
$1.24B
Einnahmen:
$322.02M
Nettoeinkommen (Verlust:
$-102.47M
KGV:
-11.87
EPS:
-1.8295
Netto-Cashflow:
$-80.57M
1W Leistung:
-21.56%
1M Leistung:
-16.49%
6M Leistung:
-33.64%
1J Leistung:
-63.59%
1-Tages-Spanne:
$20.70
$21.89
1-Wochen-Bereich:
$20.67
$27.53
52-Wochen-Spanne:
$19.35
$62.17
Procept Biorobotics Corp Stock (PRCT) Company Profile
Firmenname
Procept Biorobotics Corp
Sektor
Branche
Telefon
(650) 232-9832
Adresse
150 BAYTECH DRIVE, SAN JOSE
Compare PRCT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRCT
Procept Biorobotics Corp
|
21.72 | 1.24B | 322.02M | -102.47M | -80.57M | -1.8295 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Procept Biorobotics Corp Stock (PRCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Eingeleitet | Robert W. Baird | Neutral |
| 2026-02-26 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2026-02-26 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-12-12 | Eingeleitet | UBS | Buy |
| 2025-12-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-09 | Eingeleitet | Stephens | Overweight |
| 2025-07-07 | Eingeleitet | Oppenheimer | Perform |
| 2024-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Eingeleitet | Jefferies | Hold |
| 2023-08-11 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-31 | Eingeleitet | William Blair | Outperform |
| 2022-10-31 | Eingeleitet | BTIG Research | Neutral |
| 2022-10-25 | Eingeleitet | Truist | Buy |
| 2022-09-02 | Eingeleitet | Wells Fargo | Overweight |
| 2022-07-15 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-10-11 | Eingeleitet | BofA Securities | Buy |
| 2021-10-11 | Eingeleitet | Cowen | Outperform |
| 2021-10-11 | Eingeleitet | Goldman | Neutral |
| 2021-10-11 | Eingeleitet | Guggenheim | Buy |
| 2021-10-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Procept Biorobotics Corp Aktie (PRCT) Neueste Nachrichten
Is PROCEPT BioRobotics Corporation (PRCT) A Good Stock To Buy Now? - Insider Monkey
Top 3 Health Care Stocks You'll Regret Missing In Q2 - Benzinga
Procept Biorobotics Corp (PRCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Procept Biorobotics Corp (PRCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Procept Biorobotics Corp (PRCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Procept Biorobotics Corp (PRCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Procept Biorobotics Corp (PRCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Procept Biorobotics Corp (PRCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Procept Biorobotics Corp (PRCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Procept Biorobotics Corp (PRCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Procept Biorobotics Corp (PRCT) Institutional Confidence - TradingKey
Why is Procept Biorobotics stock sliding today? By Investing.com - Investing.com South Africa
Why is Procept Biorobotics stock sliding today? - Investing.com UK
Procept BioRobotics shares slide after Leerink downgrade cites rising competitive risks - MSN
PROCEPT BioRobotics Shares Drop After Downgrade From Leerink Partners - marketscreener.com
This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
Leerink downgrades Procept BioRobotics stock rating on competition - Investing.com UK
Leerink downgrades Procept BioRobotics stock rating on competition By Investing.com - Investing.com Canada
Procept BioRobotics EVP Nouri Alaleh sells $8,116 in stock By Investing.com - Investing.com Australia
Procept BioRobotics EVP Nouri Alaleh sells $8,116 in stock - Investing.com
PROCEPT BioRobotics Shareholders Back Board, Pay and Auditor - TipRanks
PROCEPT BioRobotics (PRCT) director receives RSU and option grants as equity pay - Stock Titan
Director Amy Dodrill receives RSUs and options at PROCEPT (NASDAQ: PRCT) - Stock Titan
PROCEPT BioRobotics (PRCT) director Mary Garrett granted RSUs and options - Stock Titan
Director at PROCEPT BioRobotics (PRCT) receives new RSU and option awards - Stock Titan
Director at PROCEPT BioRobotics (PRCT) receives RSU and stock option grants - Stock Titan
Director Frederic Moll of PROCEPT BioRobotics (PRCT) granted RSUs and options - Stock Titan
PROCEPT BioRobotics (PRCT) director receives new RSU and stock option grants - Stock Titan
Director at PROCEPT (PRCT) granted RSUs and stock options - Stock Titan
PROCEPT BioRobotics (NASDAQ: PRCT) reports 2026 shareholder vote outcomes - Stock Titan
[Form 4] PROCEPT BioRobotics Corp Insider Trading Activity - Stock Titan
PRCT (NASDAQ: PRCT) files Form 144 for 285-share sale after vesting - Stock Titan
PRCT (NASDAQ) Rule 144 notice: Director activity, 357 vested shares reported - Stock Titan
PRCT (NASDAQ) insider sale notice — 358 vested shares to be sold - Stock Titan
PROCEPT BioRobotics (PRCT) Is Up 5.7% After New WATER IV Trials Expand Aquablation Testing Scope - simplywall.st
Procept secures FDA IDE for Aquablation and completes WATER IV study enrolment - MSN
Baird initiates Procept BioRobotics stock rating at Neutral - Investing.com
Procept BioRobotics appoints Daniel Puckett to board and audit committee - Investing.com
PROCEPT BioRobotics (PRCT) Is Down 9.2% After Aquablation WATER IV MilestonesWhat's Changed - Yahoo Finance
PROCEPT BioRobotics (PRCT) Is Down 6.0% After WATER IV Trial Milestones – Has The Bull Case Changed? - simplywall.st
Procept Biorobotics wins expanded FDA IDE for Aquablation, completes study enrollment - MassDevice
Siemens Healthineers, AiM team up; Procept completes study enrollment - Yahoo Finance
PROCEPT Biorobotics® Advances Prostate Cancer Program With WATER IV Study Enrollment Completion And Expanded IDE Approval - marketscreener.com
PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval - markets.businessinsider.com
Procept BioRobotics completes enrollment in prostate cancer study By Investing.com - Investing.com South Africa
Procept BioRobotics completes enrollment in prostate cancer study - Investing.com
Finanzdaten der Procept Biorobotics Corp-Aktie (PRCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Procept Biorobotics Corp-Aktie (PRCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Waters Kevin | EVP, CFO |
Jun 08 '26 |
Sale |
28.48 |
357 |
10,167 |
151,201 |
| Templin Barry L | EVP, Chief Technology Officer |
Jun 08 '26 |
Sale |
28.48 |
358 |
10,195 |
68,953 |
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):